Mabwell (Mabwell-B) released its 2025 Environmental, Social and Governance (ESG) Report detailing significant progress across innovation, environmental management and stakeholder engagement.
R&D EXPANSION • R&D expenditure reached RMB 976.96 million, up 147.46 % of annual operating revenue, with 374 employees—over 60 % holding master’s degrees or above. • The company filed 69 new invention patent applications, lifting its cumulative portfolio to 355, with 90 approvals to date. • Key pipeline advances included Breakthrough Therapy Designation for Nectin-4 ADC 9MW2821 and FDA fast-track status for 7MW4911 and 9MW3011. Four products are commercialized; one new biologic, Albipagrastim alfa (Mailisheng®), was approved and added to China’s National Reimbursement Drug List in December.
ENVIRONMENT & CLIMATE • Greenhouse-gas emission intensity fell to 0.03 tCO₂e per RMB 1,000 of revenue, down 75 % versus 2024, aided by on-site boiler commissioning and rooftop solar deployment. • Total environmental spending reached RMB 1.98 million; compliant disposal rates for wastewater, waste gas and solid waste stayed at 100 %. • Energy-saving projects cut power use to 4,644.07 tce, while natural-gas reliance rose as part of a cleaner-energy shift.
SOCIAL RESPONSIBILITY • The employee base stood at 1,325, with a 100 % coverage of social insurance and performance evaluations. Training encompassed 1,512 sessions (77,233.5 hours), averaging 58 hours per employee. • Through the Junmaikang Public Welfare Project, Mabwell donated 17,896 vials of medication, assisting 5,263 patients; total public-welfare spending reached RMB 3.31 million. • Screening and education programmes in 17 regions of Chongqing delivered 885 bone-density tests and 28 health lectures, reaching more than 51,000 participants.
GOVERNANCE & COMPLIANCE • Independent directors constitute 33.3 % of the nine-member board; 11 board meetings reviewed 52 proposals in 2025. • All 365 key employees received anti-corruption training (900 hours), and no commercial bribery or data-privacy breaches were reported. • Supplier management covers 1,725 partners, with integrity clauses embedded in all procurement contracts; no corruption cases occurred.
OUTLOOK The board pledges to deepen ESG integration, continue pipeline progression in oncology and age-related diseases, and scale global market expansion, while maintaining its focus on resource efficiency and climate-aligned operations.
Comments